• Other competitors in the healthcare sector include: Pfizer (PFE), Biogen Idec (BIIB), and GlaxoSmithKline (GSK).

    FORBES: Earnings Preview: Amgen

  • Biogen Idec (BIIB) reports its third quarter earnings on Thursday, October 25, 2012.

    FORBES: Earnings Preview: Biogen Idec

  • Biogen (NASDAQ:BIIB) is getting a little faulty, so take caution with this one.

    FORBES: Apple Stabilizes Above $420, Google Still Selling Off

  • The reason: Biogen's (nasdaq: BIIB - news - people ) top-selling drug was another multiple sclerosis drug, Avonex.

    FORBES: Biogen Idec Hits A Nerve

  • Rituxan is sold through a joint venture between Genentech and Biogen-Idec (nasdaq: BIIB - news - people ).

    FORBES: When Doctors Go Off-Label

  • Another biotech idea is Biogen Idec ( BIIB, 141), where growth expectations are tied largely to Tysabri, a multiple sclerosis drug.

    FORBES: 7 Big Spenders With Abundant Cash

  • Today Biogen Idec (BIIB) reported top-line results of EMPOWER, a Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis (ALS).

    FORBES: Biogen Idec ALS Drug Fails

  • The trial of Genentech and Biogen Idec (nasdaq: BIIB - news - people )'s lymphoma drug, Rituxan, in diabetes progression could report results later this year.

    FORBES: Delaying Diabetes

  • Among the largest underlying components of XBI, in trading today Biogen Idec Incorporated ( BIIB) is up about 0.9%, and Ariad Pharmaceuticals Incorporated ( ARIA) is up by about 3.3%.

    FORBES: Investors Extract Gains From Biotech Sector

  • The companies that experienced the reductions are: Gilead Sciences Inc. ( GILD), Biogen Idec Inc. ( BIIB), Pall Corp. ( PLL), Onyx Pharmaceuticals ( ONXX) and Regeneron Pharmaceuticals ( REGN).

    FORBES: Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter

  • Biogen Idec Inc. ( BIIB - news - people ), experienced sharp upward shifts in share price as well as in options implied volatility following the news.

    FORBES: Options Flash

  • Teva makes Copaxone, a treatment for multiple sclerosis that competes with the MS drugs made by Biogen Idec (nasdaq: BIIB - news - people ) and Serono.

    FORBES: Teva Takes On Novartis

  • Investors immediately threw a party for Elan (nyse: ELN - news - people ) and its marketing partner Biogen Idec (nasdaq: BIIB - news - people ).

    FORBES: Cheers For Elan, Biogen-Idec

  • One interesting case is Biogen-Idec (BIIB) which built a huge campus at the intersection of Route 128 and Route 20 in the tony suburb of Weston while maintaining a research facility in Cambridge.

    FORBES: How MIT's Kendall Square Attracted $2 Billion And So Can You

  • In the options pits, traders have bought to open almost five BIIB calls for every put on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) during the past two weeks.

    FORBES: Biogen Idec Has Fallen And Can't Get Up, How To Play It With Options

  • Among the largest underlying components of IYH, in trading today Biogen Idec Inc ( NASD: BIIB) is up about 2.7%, Allergan, Inc ( NYSE: AGN) is up about 1.1%, and Covidien Plc ( NYSE: COV) is up by about 0.9%.

    FORBES: IYH, BIIB, AGN, COV: ETF Outflow Alert

  • Among the largest underlying components of IBB, in trading today Gilead Sciences, Inc. ( NASD: GILD) is down about 0.5%, Celgene Corp. ( NASD: CELG) is off about 1.4%, and Biogen Idec Inc ( NASD: BIIB) is lower by about 0.8%.

    FORBES: IBB, GILD, CELG, BIIB: Large Inflows Detected at ETF

  • Among the largest underlying components of IBB, in trading today Alexion Pharmaceuticals Inc. ( NASD: ALXN) is up about 0.1%, Biogen Idec Inc ( NASD: BIIB) is up about 0.8%, and Perrigo Company ( NASD: PRGO) is relatively unchanged.

    FORBES: Notable ETF Inflow Detected - IBB, ALXN, BIIB, PRGO

  • Among the largest underlying components of XBI, in trading today Biomarin Pharma Incorporated ( NASD: BMRN) is up about 0.3%, Regeneron Pharmaceutical Incorporated ( NASD: REGN) is up about 0.3%, and Biogen Idec Incorporated ( NASD: BIIB) is lower by about 0.1%.

    FORBES: Investors Lower Exposure To Biotech -- REGN, BIIB, BMRN In Focus

  • Among the largest underlying components of IXJ, in trading today Gilead Sciences Incorporated ( NASD: GILD) is down about 1.6%, Baxter International Incorporated ( NYSE: BAX) is off about 2.4%, and Biogen Idec Incorporated ( NASD: BIIB) is lower by about 1.6%.

    FORBES: Notable ETF Outflow Detected - IXJ, GILD, BAX, BIIB

  • Among the largest underlying components of FBT, in trading today Biogen Idec Incorporated ( NASD: BIIB) is up about 6.8%, Myriad Genetics Incorporated ( NASD: MYGN) is up about 3.9%, and Vertex Pharmaceuticals Incorporated ( NASD: VRTX) is higher by about 1.8%.

    FORBES: Noteworthy ETF Inflows: FBT, BIIB, MYGN, VRTX

  • Among the largest underlying components of XBI, in trading today Spectrum Pharmaceuticals Inc ( NASD: SPPI) is down about 1.9%, Onyx Pharmaceuticals, Inc. ( NASD: ONXX) is off about 1.2%, and Biogen Idec Inc ( NASD: BIIB) is lower by about 1.9%.

    FORBES: XBI, SPPI, ONXX, BIIB: ETF Inflow Alert

  • "These things don't get immediately disentangled, " says Church, who worked in the medical biotech business as a researcher in the early days of Biogen, now part of Biogen Idec (nasdaq: BIIB - news - people ), before coming to Harvard.

    FORBES: BP's Biotech Bet

  • She and Rauch both point out that Elan is a lot more likely to benefit from Antegren sales than Biogen-Idec (nasdaq: BIIB - news - people ), which may have to cannibalize sales of its existing MS treatment Avonex to sell Antegren.

    FORBES: Elan, ImClone Lose, Celgene Wins

  • Genentech (nyse: DNA - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ) said Tuesday that a key study of the drug Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.

    FORBES: Lupus Treatment Evades Genentech, Biogen

  • Since taking over at ImClone, he's installed one director from his own firm and two others that may be friendly to him, including a Harvard Medical School professor Icahn also nominated for the board of Biogen Idec (nasdaq: BIIB - news - people ) when he sought to take control there.

    FORBES: BristolClone? Watch Wilmington.

  • After one death due to an apparent side effect, Biogen (nasdaq: BIIB - news - people ) and partner Elan (nyse: ELN - news - people ) pulled their multiple sclerosis drug Tysabri, which had been approved with rapid speed by the Food and Drug Administration only four months before.

    FORBES: Safety Vs. Efficacy

  • For biotech drug maker Biogen Idec ( BIIB), the last couple years have been a bit unsettling, what with activist investor Carl Icahn dropping broad hints about a breakup or sale, ongoing problems with its most promising drug, and the arrival last summer of a new CEO with his own ideas about how the company should be run.

    FORBES: Is Biogen A Bad Bet Or A Bargain?

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定